▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1204 by analyst upside · 2026-09-09
CRSP
CRISPR Therapeutics AG
Healthcare · Market Cap $5B · P/E 0x
ANALYST PRICE TARGET
+59.8%
implied upside to consensus target
Current Price $54.78
Consensus Target $87.56
Bull Target $291.0
Bear Target $44.0
Analysts Covering 18
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
7
Hold
7
Sell
0
52-Week Low $44.12
52-Week High $78.48
YTD Return +1.9%
FUNDAMENTALS
Market Cap $5B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-4.71
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $13M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $44.12
52-Week High $78.48
Current Price $54.78
Bear Target $44.0
Bull Target $291.0
● Now $54.78 ● Target $87.56
TRADING DATA
Avg Volume 1.6M
YTD Return +1.9%
Analyst Count 18
Consensus Buy
Upside to Target +59.8%
Last Updated 2026-09-09

ANALYST SUMMARY

CRISPR Therapeutics AG (CRSP) is currently trading at $54.78 with a Wall Street consensus price target of $87.56, implying potential upside of 59.8% over the next 12 months. 18 analysts currently cover CRSP, with a consensus rating of Buy - 61% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $291.0, while the most cautious has a target of $44.0.

CRSP operates in the Healthcare sector with a market capitalisation of $5B. The stock is up 1.9% year-to-date and is currently trading near the lower end of its 52-week range of $44.12 – $78.48.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

GRFS +40.2%
Grifols, S.A.
$5B · P/E 10.1x · Buy
INDV +42.8%
Indivior Pharmaceuticals, Inc.
$4B · P/E 12.3x · Buy
ACAD +23.3%
ACADIA Pharmaceuticals Inc.
$5B · P/E 12.4x · Buy
CAI +11.0%
Caris Life Sciences, Inc.
$7B · P/E 2.6x · Buy
PACS +35.1%
PACS Group, Inc.
$7B · P/E 25.5x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for CRSP, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Citizens reit
Market Outperform → Market Outperform 2026-08-31 Building track record
Needham reit
Buy → Buy 2026-08-31 20% win rate (5 calls)
Citizens reit
Market Outperform → Market Outperform 2026-08-25 Building track record
Citigroup - Reiterated
Buy → Buy 2026-08-04 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-07-08 31% win rate (48 calls)
Citizens reit
Market Outperform → Market Outperform 2026-07-06 Building track record
Bernstein - Reiterated
Market Perform → Market Perform 2026-05-13 Building track record
Citigroup - Reiterated
Buy → Buy 2026-05-06 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
36
out of 100
Coverage depth
22/30
Consensus clarity
0/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →